Norwood, MA (PRWEB) December 03, 2013
On November 18, BioPharm Insight released its 3Q13 Licensing League Tables Report, reflecting an 18% decrease in pharmaceutical licensing by value since 2Q13. BioPharm Insight, part of Infinata, Inc., is a leading provider of business intelligence solutions and belongs to the Financial Times Group.
“BioPharm Insight subscribers have a distinct advantage with our quarterly Licensing League Tables,” said Ruth McHenry, Infinata’s managing director. “It fuels their ability to make strategic long-term decisions about the competitive drug development market, using critical information before it’s available anywhere else.”
The third quarter saw 120 agreements in the life sciences industry, with an aggregate disclosed value of $6.3 billion, a decrease from 2Q13, in which 121 agreements worth $7.6 billion were announced. The agreement between Ablynx and AbbVie, involving the drug ALX-0061, was the largest deal in 3Q13, potentially valued at $840 million.
Law firms Goodwin Procter and Duane Morris top the Global Licensing League Tables of Legal Advisors for the quarter. Based on information only available to editors at BioPharm Insight, Goodwin Procter tops the value table, having advised on three pharmaceutical drug licensing agreements, valued at $1.2 billion. Duane Morris leads the volume table with five transactions worth USD $933 million.
About BioPharm Insight
BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists m
Copyright©2012 Vocus, Inc.
All rights reserved